This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or registerLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutPrevention
Prevention

The current World Federation of Hemophilia guidelines for the management of haemophilia were developed using a formal evidence and consensus-based methodology that involved multidisciplinary healthcare professionals and well-informed people living with haemophilia.1

​​​​​​​In addition to the WFH guidelines, the British Society for Haematology have produced evidence-based guidelines to summarise best practice for the assessment and management of people living with haemophilia.2,3 

Nimenrix®

(meningococcal groups A, C, W-135 and Y conjugate vaccine) 

Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y.1

View Nimenrix Summary of Product Characteristics
LoadingTrumenba®

(meningococcal group B vaccine (recombinant, adsorbed))

Trumenba is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B.2

View Trumenba Summary of Product Characteristics
Loading
References:Nimenrix®. Summary of Product Characteristics.Trumenba®. Summary of Product Characteristics.European Centre for Disease Prevention and Control (ECDC). Factsheet about meningococcal disease. Available at: https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet Last Accessed August 2022.Mbaeyi, S., Duffy, J., McNamara, L.A. Meningococcal Disease. In: Hall, E., Wodi, A.P., Hamborsky J, et al., eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Centers for Disease Control and Prevention (CDC). Washington DC: Public Health Foundation; 2021.
TreatmentRead the WFH guidelines (3rd edition) Read the guidelines What is Meningococcal Disease?

Meningococcal disease refers to any illness caused by the bacterium Neisseria meningitidis.3 There are six common serogroups of bacteria that cause most meningococcal disease worldwide - A, B, C, W, X and Y.4

 Find out more Loading

Legal Category: S1A
Further information is available upon request

PP-NIM-IRL-0028 Date of Preparation: September 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.